Financial Performance - The company's revenue for Q1 2024 reached ¥544,935,917.11, representing a 26.22% increase compared to ¥431,749,545.61 in the same period last year[5] - Net profit attributable to shareholders was ¥1,287,194.84, a significant turnaround from a loss of ¥6,174,718.09 in Q1 2023, marking a 120.85% improvement[5] - The net cash flow from operating activities was ¥33,406,639.56, compared to a negative cash flow of ¥65,298,553.10 in the previous year, reflecting a 151.16% increase[5] - The company reported a basic earnings per share of ¥0.0033, a 121.43% increase from a loss of ¥0.02 per share in Q1 2023[5] - The total operating revenue for Q1 2024 was CNY 544,935,917.11, an increase of 26.2% compared to CNY 431,749,545.61 in the same period last year[25] - The net profit for Q1 2024 was ¥1,379,353.57, a significant recovery from a net loss of ¥4,361,228.42 in the same period last year[26] - The total comprehensive income for Q1 2024 was ¥2,822,492.01, compared to a loss of ¥3,866,854.86 in Q1 2023, indicating a positive turnaround[27] - Basic and diluted earnings per share for Q1 2024 were both ¥0.0033, recovering from a loss of ¥0.0154 per share in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥7,564,260,512.20, up 7.19% from ¥7,056,973,990.05 at the end of the previous year[5] - Total liabilities increased to CNY 1,653,654,685.73, compared to CNY 1,141,952,647.75, reflecting a growth of 45.0%[23] - The company's total equity decreased slightly to CNY 5,910,605,826.47 from CNY 5,915,021,342.30, a decline of 0.1%[23] - The company's short-term borrowings rose by 222.15% to ¥494,646,798.58, attributed to increased financing activities[10] - The company's total liabilities increased, with current liabilities showing a dramatic rise of 1805.11% due to the reclassification of long-term borrowings[10] Cash Flow - The net cash flow from investing activities improved by 192.57%, reaching ¥196,142,729.39, mainly due to the maturity of certain financial products[14] - The company reported a net cash inflow from investing activities of ¥196,142,729.39, a significant improvement from a net outflow of ¥211,878,225.67 in Q1 2023[30] - Cash and cash equivalents increased to CNY 1,395,609,123.31 from CNY 776,195,507.20, representing an increase of 79.9%[22] - The cash and cash equivalents at the end of Q1 2024 totaled ¥1,083,014,702.47, up from ¥597,618,503.71 at the end of Q1 2023, indicating a strong liquidity position[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,346[15] - The top 10 shareholders hold a total of 45% of shares, with 中红普林集团有限公司 holding 175,500,000 shares (45.00%) and 厦门国贸控股集团有限公司 holding 59,085,000 shares (15.15%)[15] - The company initiated a share buyback program, repurchasing 290,000 shares, which represents 0.0744% of the total share capital[18] - The total number of restricted shares at the end of the period is 267,161,700, with 中红普林集团有限公司 holding 175,500,000 shares[17] - The company plans to lift restrictions on certain shares on April 27, 2024, including 175,500,000 shares held by 中红普林集团有限公司[17] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[15] - The company has not disclosed any other relationships among the top 10 unrestricted shareholders[15] - The company aims to stabilize its stock price through the buyback program initiated in March 2024[18] - The company has not reported any preferred shareholders or changes in restricted shares during the reporting period[16] Research and Development - Research and development expenses increased by 81.76% to ¥9,612,140.03, primarily due to mergers and acquisitions[12] - Research and development expenses increased to ¥9,612,140.03, up from ¥5,288,254.19, highlighting the company's commitment to innovation[26] Inventory and Receivables - Accounts receivable rose to CNY 422,251,352.16, up 22.4% from CNY 345,036,419.03[22] - Inventory increased to CNY 547,355,266.90, a rise of 8.5% compared to CNY 504,876,281.32[22] - Total current assets reached CNY 4,709,692,660.21, up 18.0% from CNY 3,997,261,836.10[22] - The company reported a significant increase in contract liabilities to CNY 80,174,097.18, up 34.3% from CNY 59,706,335.43[23]
中红医疗(300981) - 2024 Q1 - 季度财报